Orexigen Therapeutics Inc (OREX.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2016||Independent Chairman of the Board|
|57||2016||President, Chief Executive Officer, Director|
|46||2016||Chief Financial Officer, Senior Vice President|
|55||2016||Chief Operating Officer, Executive Vice President, President - Global Commercial Products|
|50||2015||Executive Vice President, General Counsel, Secretary|
- BRIEF-Orexigen Therapeutics Says Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 Mln
- BRIEF-Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics
- BRIEF-Orexigen Says Entered Into Exchange Agreements With Holders
- CORRECTED-UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs
- BRIEF-Orexigen Therapeutics Q3 loss per share $1.35